Andrew J. Pierce

High Impact

Senior Vice President

Ouachita Baptist University

faculty

34 h-index 171 pubs 7,483 cited

Research Areas

Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers DNA Repair Mechanisms Monoclonal and Polyclonal Antibodies Research Metabolomics and Mass Spectrometry Studies Cancer-related molecular mechanisms research Pharmacological Effects and Toxicity Studies

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Andrew J. Pierce's research focuses on the development and evaluation of novel cancer therapies, particularly those targeting DNA damage response pathways and immune checkpoint proteins. He has investigated the efficacy of the ATR kinase inhibitor ceralasertib, both as a monotherapy and in combination with chemotherapy agents like carboplatin and paclitaxel. His work also explores the potential of ceralasertib to enhance cancer immunotherapy by modulating the tumor microenvironment.

Further investigations by Pierce include the development of bispecific antibodies, such as the Humabody CB213, which co-targets PD-1 and LAG-3 on T cells to promote anti-tumor activity. He also examines the role of CBL ubiquitin ligases as targets in cancer immunotherapy and the development of dual-targeting costimulatory Humabody VH therapeutics like CB307 for PSMA-positive tumors. Pierce's research also involves the utilization of targeted mass spectrometry for quantifying pharmacodynamic biomarkers of kinase inhibition and the retrospective analysis of biomarkers like Schlafen11 (SLFN11) to predict treatment outcomes.

Metrics

h-index: 34
Publications: 171
Citations: 7,483

Selected Publications

High-Throughput HPLC Method for the Measurement of Octanol–Water Partition Coefficients without an Organic Modifier (2025) DOI
Ritualistic Male–Male Combat of the Northern King Cobra (<scp>Ophiophagus hannah</scp>) in Thailand (2025) DOI
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors (2025) DOI
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets (2024) DOI
Nest site vegetation structure influences nest predators and nesting success of understory birds in a dry evergreen forest in northeastern Thailand (2024) DOI
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum (2024) DOI
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors (2024) DOI
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024) DOI
Non-breeding season records of warblers in the Phylloscopus reguloides lineage from Thailand and Myanmar (2023) DOI
Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023) DOI
Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023) DOI
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023) DOI
Data from Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition (2023) DOI
Data from Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition (2023) DOI
Data from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023) DOI